MedImmune, LLC
One MedImmune Way
Gaithersburg
Maryland
20878
United States
Tel: 301-398-0000
Fax: 301-398-9000
Website: http://www.medimmune.com/
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
352 articles with MedImmune, LLC
-
MedImmune: Collaboration With Trellis Bioscience, Inc. Strengthens RSV Pipeline
12/8/2009
-
Trellis Bioscience, Inc. Grants MedImmune (JOBS) License for Its Anti-RSV Antibodies in Deal Worth Potentially $338 Million
12/1/2009
-
MedImmune to Present Four Abstracts on RSV and Influenza at 47th Annual IDSA Meeting
10/30/2009
-
Interim Clinical Trial Results Show MedImmune's H1N1 Vaccine Has Similar Safety Profile as Seasonal Vaccine in Eligible Children and Adults H1N1 Immunogenicity Profile Also Consistent with Seasonal Vaccine Formulations
10/23/2009
-
MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
10/16/2009
-
MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
9/22/2009
-
To-BBB technologies BV Will Be Used By MedImmune To Evaluate Brain Drug Delivery Mechanism
9/17/2009
-
US FDA Approves Sanofi-Aventis (France), CSL Limited, MedImmune (JOBS), Novartis AG (JOBS) H1N1 Vaccine, Says Enough for Everyone
9/16/2009
-
Seattle Genetics, Inc. Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune
8/10/2009
-
MedImmune Advances Three Oncology Programs Into the Clinic
8/10/2009
-
MedImmune's Nasal Vaccine Holds Promise Against Swine Flu
7/31/2009
-
MedImmune Release: FluMist(R) Begins Shipping for 2009-2010 Influenza Season
7/28/2009
-
Catalyst Biosciences, Inc. Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics; Catalyst Will Receive Milestone up to $195 Million
7/7/2009
-
MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
6/30/2009
-
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
6/30/2009
-
MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
5/5/2009
-
MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research
4/16/2009
-
La Jolla Institute for Allergy and Immunology Signs Exclusive License Agreement With MedImmune On Major Asthma Discovery
2/25/2009
-
Medarex, Inc. to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
2/2/2009
-
Xenome Ltd Grants MedImmune License to xdiscover(TM) Venom Peptide Library
1/8/2009